宣泰医药: 2025年半年度报告摘要

Core Viewpoint - Shanghai Xuantai Pharmaceutical Technology Co., Ltd. reported stable core business operations and no significant adverse changes in its core competitiveness, with a proposed cash dividend distribution plan for shareholders [1]. Financial Summary - Total assets at the end of the reporting period were approximately CNY 1.44 billion, a decrease of 0.68% compared to the previous year [3]. - Operating revenue for the first half of 2025 was approximately CNY 219.61 million, reflecting a slight increase of 0.74% year-on-year [3]. - Total profit for the period was approximately CNY 51.03 million, down 13.89% from the previous year [4]. - Net profit attributable to shareholders of the listed company was not specified, but the basic earnings per share decreased by 16.67% to CNY 0.10 [4]. - The cash dividend proposed is CNY 0.25 per 10 shares, amounting to a total of approximately CNY 11.23 million, which represents 24.62% of the net profit attributable to shareholders for the first half of 2025 [1]. Shareholder Information - The total number of shareholders at the end of the reporting period was 8,020 [4]. - Major shareholders include Shanghai Lianhe Investment Co., Ltd. and Finer Pharma Inc., with specific shareholding percentages detailed [5].